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Background: Concurrent chemo-radiotherapy is demonstrately superior to sequential chemo-radiotherapy in the
treatment of advanced Non-Small-Cell Lung Cancer not suitable for surgery. Docetaxel is considered to enhance
the cytotoxic effect of radiotherapy on the tumour cells. Tomotherapy (HT) is a novel radiotherapeutic technique,
which allows the delivery of Image Guided-IMRT (IG-IMRT), with a highly conformal radiation dose distribution.
The goal of the study was to estimate tolerability of Docetaxel concurrent with IMRT and to find the maximum
tolerated dose of weekly Docetaxel concurrent with IMRT delivered with HT Tomotherapy after induction
chemotherapy with Cisplatin and Docetaxel in patients affected with stage III Non-Small Cell Lung Cancer.
Methods: We designed a phase I, dose-finding study to determine the dose of weekly Docetaxel concurrent
with Tomotherapy after induction chemotherapy, in patients affected by Non-Small Cell Lung Cancer with Stage
III disease, not suitable for surgery.
Results: Concurrent weekly Docetaxel and Tomotherapy are feasible; we did not reach a maximum tolerated
dose, because no life-threatening toxicity was observed, stopping the accrual at a level of weekly docetaxel
38 mg/m2, a greater dose than in previous assessments, from both phase-I studies with weekly docetaxel alone
and with Docetaxel concomitant with standard radiotherapy.
Conclusions: Concurrent weekly Docetaxel and Tomotherapy are feasible, and even with Docetaxel at
38 mg/m2/week we did not observe any limiting toxicity. For those patients who completed the combined
chemo-radio treatment, median progression-free survival (PFS) was 20 months and median overall survival
(OS) was 24 months.Background
Concurrent chemo-radiotherapy is considered the standard
treatment for patients affected by locally advanced, stage
III, unresectable Non-Small Cell Lung Cancer (NSCLC)
and good performance status (PS) [1]. Stage III NSCLC
constitutes a heterogeneous group, likely due to a different
nodal involvement; its median survival has been recently
updated from 12 to 23.3 months in phase III trials [2,3].* Correspondence: abearz@cro.it
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reproduction in any medium, provided the orThe recommended systemic treatment in stage III NSCLC
consists of 2–4 cycles of platin-combination with concur-
rent radiotherapy [4]. In an effort to improve overall sur-
vival (OS) different schemes for both induction and
consolidation therapy are used in clinical practice, with in-
duction chemotherapy before the start of concurrent
chemo-radiotherapy preferred by some [2,5] and consoli-
dation modalities preferred by others [3,6]. However, no
clear superiority has been demonstrated between those
two approaches. Docetaxel enhances the cytotoxic ef-
fects of radiotherapy in vitro [7]. In several phase II
studies radiotherapy with concurrent Docetaxel andtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Bearz et al. BMC Cancer 2013, 13:513 Page 2 of 7
http://www.biomedcentral.com/1471-2407/13/513after induction with Cisplatin-Docetaxel combinations
has been shown to be feasible [8,9], with encouraging
OS rates. There is an indication that higher radiation
doses may result in improved probability of local
tumour control [10]; however, using current radiation
delivery techniques dose escalation, in particular in
combination with chemotherapy, may lead to unaccept-
able lung toxicity. Therefore, the search for better radio-
therapy approaches is important and Tomotherapy (HT)
may be one of the most promising technologies for this
purpose [11]. HT is a novel technique, which allows the
delivering of Image Guided - IMRT (IG-IMRT), by using
a dynamic delivery in which gantry, treatment couch, and
multileaf collimator leaves are all in motion during treat-
ment, resulting in a highly conformal radiation dose distri-
bution [12]. The development of those techniques has led
to improved radiation delivery with better tumor coverage
and decreased exposure of surrounding normal tissues;
however, in the CALBG 30105 study [13] the arm with
Gemcitabine concurrent with high dose conformal radi-
ation treatment was closed for high rate of severe pulmon-
ary toxicities, likely due to larger mean lung doses;
however the authors suggest that radiosensitizing proper-
ties of Gemcitabine on normal tissue may have contrib-
uted to the higher pulmonary toxicity observed [14]. On
this basis, we were concerned that, using a radiosensitizer
agent such as Docetaxel concurrent with Tomotherapy,
with larger volumes of healthy lung treated with low dose
radiation, could lead to a different maximum tolerated
dose (MTD) for Docetaxel.
We designed a phase I, dose-finding study to estimate
the tolerability of concurrent Docetaxel with Tomother-
apy and to determine the MTD of weekly Docetaxel
concurrent with IMRT delivered with HT after induction
chemotherapy. We chose to study Docetaxel alone com-
bined with concurrent HT, because Docetaxel may en-
hance both activity and toxicity of radiotherapy and we
did not want to have any confounding bias in the results
analysis. For this reason we chose to deliver the back-
bone of systemic treatment for NSCLC, i.e. platinum, in
the induction part, using Docetaxel alone in the concur-
rent study.
Methods
This was a mono-institutional, phase I, dose-finding study.
Enrolment started in March 2008 and was closed in
June 2011. Eligible patients were male or non-pregnant
and non-breast feeding females, aged more than 18 years,
PS ECOG 0 or 1, with histologically or cytologically con-
firmed NSCLC with multiple clinical-level N2 or N3 for
mediastinal lymph nodes, above the 15 mm short-axis
threshold at Computed Tomography (CT) scanning. Pa-
tients with supraclavicular involvement of lymph nodes
and pleural effusion were excluded. Fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) fu-
sions with CT (PET-CT), as well as CT-scans of the
thorax, blood tests and pulmonary function tests were
mandatory at baseline. Patients must have adequate organ
function including the following: bone marrow reserve
(white blood cell count ≥3.0 × 109/L, absolute neutrophils
count ≥1.5 × 109/L), hepatic function (bilirubin ≤1.5 times
upper limits of normal [x ULN] and alkaline phosphatase,
aspartate transaminase and alanine transaminase ≤2.5 ×
ULN), and renal function (serum creatinine ≤1.5 × ULN).
Screening assessments were carried out within 28 days of
the first dose of chemotherapy. The treatment protocol
was reviewed and approved by the competent authorities
and the institutional ethics committee and was registered
with the authorities (European Union Drug Regulating
Authorities Clinical Trial no. EUDRACT 2008-001074-
33). Each patient signed an informed consent document.
Treatment plan
In the induction part all patients received three cycles of
Cisplatin 80 mg/ m2 and Docetaxel 75 mg/m2 on day 1,
every three weeks. A PET-CT scan was repeated after
the third cycle and patients with stable disease or par-
tial/complete response were included in the phase I
radiotherapy concurrent with chemotherapy protocol.
The phase I, dose-escalation trial consisted of 5 weeks of
once-weekly Docetaxel (on day 3 of every week) concur-
rent with radiotherapy at a dose of 2,4 Gy/day for
5 days/week for 5 consecutive weeks to a total dose of
60 Gy. Docetaxel dosage was scheduled as 10 mg/m2
weekly for the first 3 patients; if no severe toxicity oc-
curred, the next 3 patients were to be treated with Doce-
taxel 13 mg/m2/week, and so on according to a modified
Fibonacci 3 + 3 design [15]. The dose was escalated in
cohorts of 3 patients and 3 mg/m2 were added to every
cohort. The choice to add 3 mg/m2 at each cohort in-
stead of the 67% of the starting dose like in Fibonacci
design was due to the absence of information about HT
concurrent to chemotherapy. At the time this protocol
was planned, it was only known the dose limitation of
30 mg/m2/week for Docetaxel concomitant with radio-
therapy [16]; for this reason the dose was increased with
caution. Dose-limiting toxicities were defined as grade
(G) 4 thrombocytopenia, or at least G2 bleeding, G4
neutropenia, or febrile neutropenia, G3 nausea, vomiting
or diarrhoea; unexpected G2 toxic effects needing dose
reduction or delay in the concurrent treatment were also
classified as dose limiting. In the case of at least one se-
vere toxicity, 3 more patients had to be added at that
level and, if again severe toxicity occurred within the
same cohort, that dose was to be considered the max-
imum tolerated dose, with the previous level chosen as
the dose to use in concurrent modality with HT. Ad-
verse events were graded according to National Cancer
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(version 3.0) [17].
Chemotherapy
Docetaxel was administered in a 60-minute i.v. infusion,
both in induction (75 mg/m2 every three weeks) and
concurrent therapy (weekly and with dose-escalation).
The standard prophylaxis to prevent hypersensitivity re-
actions included a single intravenous administration of
corticosteroids and histamine-blocking drugs just before
Docetaxel infusion. Induction Cisplatin 80 mg/m2 was
administered as a 60-minutes i.v. infusion immediately
following the Docetaxel infusion. Hydration and prophy-
lactic antiemetics were administered before chemother-
apy. In the induction part dose modifications allowed
due to toxicity were: Docetaxel 75% for febrile neutropenia,
G4 neutropenia, febrile neutropenia, G4 thrombocytopenia,
G ≥3 mucositis; and Cisplatin 75% for nephrotoxicity G ≥ 2.
Concurrent chemo-radiotherapy
No dose modifications for Docetaxel in concurrent mo-
dality were allowed. Docetaxel was administered on day
3 every week of radiotherapy, and thoracic radiotherapy
was started 30 minutes after infusion.
Radiotherapy
Patients underwent a volumetric treatment-planning CT
scan using an individualized immobilization device in
the treatment position on a flat table. The gross tumour
volume (GTV), planning target volume (PTV) and plan-
ning organ at risk volume (PRV) were delineated accord-
ing to the International Commission on Radiation Units
and Measurements (ICRU) Report 62 guidelines. The re-
staging FDG-PET/CT performed before radiation ther-
apy was co-registered to the treatment-planning CT to
improve the target delineation. The GTV included the
primary tumour and any FDG-avid regional lymph
nodes. For this study, the clinical target volume was
equivalent to the GTV. Elective nodal regions were not
intentionally irradiated. The PTV volume included the
GTV with a minimal 3D margin of 10 mm. A 4D CT-
scan was used to check GTV and PTV margins with re-
spect to physiologic ventilatory tumour excursion. The
dose prescribed to the PTV was 60 Gy delivered in 25
fractions (2.4 Gy/fraction), so that 95% of the PTV re-
ceived the 98% of the prescribed dose. Using the linear
quadratic model and the BED equation derived from this
model, assuming an α/β ratio of 10 Gy, this prescription
would be equivalent to 66 Gy in a standard 2-Gy frac-
tionation [18,19]. There are two modalities of shortening
overall time of radiotherapy without increasing late com-
plications and allowing for better efficacy outcomes: first
is two fractions per day, second is using fewer and larger
doses [20,21]. We used a relatively hypofractionatedradiation regimen based on the second modality. Spe-
cific dosimetric guidelines were the following: spinal
cord maximum dose <46 Gy; mean lung dose <14 Gy;
lung V20 (percentage of lung receiving 20 Gy) <25%.
Treatment was delivered once a day, five fractions
weekly. All patients were treated with HT [11]. A Mega-
volt CT-scan was also performed daily for each patient to
image-guide the radiation treatment, no adaptive radio-
therapy was performed. Patients were seen weekly during
the radiotherapy course to determine the presence of
symptoms.
Patient evaluation
All patients underwent a full physical examination (in-
cluding determination of performance status, weight
loss, vital signs), and haematological test at baseline and
then weekly during induction and concurrent therapy.
They also underwent a biochemistry test at baseline and
every 3 weeks during induction and concurrent treat-
ment. Chest CT was mandatory and brain CT was per-
formed if clinically indicated; all patients had multi-level
N2 or N3 involvement demonstrated both by CT scan
and PET-CT. Tissue or cytologic diagnosis was made
using biopsy/brushing or bronchial aspirate obtained
during fibre-optic bronchoscopy or, alternatively, trans-
thoracic aspiration biopsy of the primary tumour. CT-PET
scan was performed ≤2 weeks before starting induction
chemotherapy and local chemo-radiotherapy, respectively,
and was repeated every 4 months during follow-up, start-
ing two months after the end of concomitant treatment.
PET/CT scans were performed using a combined PET
and CT system (Discovery LS PET CT, GE Healthcare,
Milwaukee, WI, USA). Patients were fasting for at least
6 hours before tracer injection and each patient received
350–400 MBq of FDG (18 F-Fluoro-2-deoxy-D-glucose)
intravenously. PET/CT acquisitions were carried out at
60 minutes post tracer-injection, after the patients
waiting for the scan were kept at rest in a quiet, dimly
lit room. A whole-body PET/CT scan, consisting of
helical CT scanning from the head through the pelvis
(rotation time 0.8 s, slice thickness 5 mm, image inter-
val 4.25 mm, X-ray voltage 140 kV and X-ray current
80–140 mA), followed by a 2D PET acquisition (six or
seven bed positions at 5 min per bed position) was per-
formed in all patients. Immediately after being acquired,
images were reconstructed using ordered subsets expect-
ation maximization 2D iterative reconstruction; CT im-
ages were used to produce attenuation correction values
for PET emission reconstruction and fused PET/CT pres-
entation, in order to avoid misinterpretation between
inflammatory pathology and tumour. PET data were
interpreted independently of the result of any prior in-
vestigation by two nuclear medicine physicians in con-
sensus, expert in oncological imaging. Any focal FDG
Table 1 Demographics of 37 patients
Patients (%)
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higher than the surrounding background activity was
used as a PET criterion for malignancy. In particular,
high focal lung tracer uptake was interpreted as cancer
uptake in disease staging and as persistent disease in
re-staging. Focal activity in mediastinal lymph nodes
was considered as metastatic disease when consistent
with an abnormal volumetric size by CT-scan. Assess-
ment of FDG uptake was made visually, comparing
PET/CT studies of the same patient, considering the
visual increasing or decreasing FDG uptake in the lesions
together with RECIST morphological criteria of response.
The standardized uptake value of FDG uptake (SUV) was
used as an accessory reference only. The results of
PET-CT were then classified as progressive disease,
stable disease, or partial and complete remission in accord-
ing to both PET visual FDG uptake analysis and CT
morphological criteria.
The primary endpoint was safety and toxicity of Doce-
taxel concurrent with Radiation Therapy after induction
treatment in order to define the maximum dose level.
Any treatment-related side effects were followed until
resolution. Tumour response was assessed according to
RECIST criteria 3.0 [22].
The efficacy of treatments was evaluated in all patients
who were allocated to induction treatment; response rate
was recorded and follow-up for progression free survival
(PFS) and overall survival (OS) was maintained till pro-
gression and death for all patients who completed the
induction and concurrent treatment. Kaplan-Meier
methods were used to assess PFS and OS [23].
Results
The first patient was enrolled in January 2008, the last
one in January 2011. Analysis was done in June 2012; a
total of 37 patients were treated. Four patients (10%) out
of 37 did not go into the concurrent chemo-radiotherapy,
2 because of progression of disease after the induction
therapy and 2 because of consent withdrawal. Patients’
characteristics are summarized in Table 1. Seven patients
were female (19%) and 30 males (81%); median age was
61 years (range 40–77), 16 patients were affected by squa-
mous cell carcinoma (43%) and 20 by adenocarcinoma
(54%); one patient (3%) had an undifferentiated histology.
For 23 patients only EGFR mutational analysis was pos-
sible, and only one patient (4%) harboured a mutation at
exon 21. About Performance Status according to ECOG
scale at diagnosis, 22 patients (60%) had PS 0, and 15
(40%) had PS 1. Fifteen patients (40%) had stage IIIA and
22 (60%) IIIB disease. Docetaxel was reduced at 75% of
the planned dose for toxicity in 4 patients (11%) during
the induction treatment: 2 patients showed mucositis G3,
one patient had nausea G3 and one patient suffered from
atrial fibrillation. During induction therapy, 5 patients(13%) reported neutropenia G3, and 3 (8%) neutro-
penia G4 without fever. G-CSF was used as primary
prophylaxis in 11 patients (30%), from cycle II in the
induction treatment. No thrombocytopenia or anaemia
greater than G1 was recorded. Three patients had nau-
sea G3 and one patient reported diarrhoea G3 in the
induction phase. All 37 patients were evaluable for re-
sponse to induction chemotherapy: the ORR was 31/37
(84% all partial responses), 2 progressive diseases (5%),
and 4/37 patients were stable (10%). Thirty-three pa-
tients were subsequently enrolled into the phase I dose
escalation study, with concurrent chemo-radiotherapy.
All 33 patients received the planned radiotherapy total
dose of 60 Gy and weekly Docetaxel; each cohort re-
ceived 3 mg/m2 more of weekly docetaxel, starting
Figure 1 Progression free survival of 33 patients with lung cancer, stage III, not operable and treated with induction chemotherapy
and radiotherapy.
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haematological toxicities were recorded in the concurrent
treatment, 2 patients had leucopoenia G2; radiation pneu-
monitis were never reported; no patient reported diar-
rhoea; esophagitis was G2 in 7/33 patients (21%), and G3
in one patient (3%). No late oesophageal toxicity was ob-
served. Docetaxel dose-escalation followed the standard
3 + 3 rule, starting from 10 mg/m2/week. In the ab-
sence of dose-limiting toxicity (DLT), we decided to
stop at a dose of 38 mg/m2/week, a greater dose than
previous assessments in phase-I studies with weekly
docetaxel alone [24].
Response at the first PET-CT scan after the end of
concurrent chemo-radiotherapy was as follows: 28 pa-
tients (85%) showed a partial response, 2 patients (6%)
had a progression of disease, 2 patients were stable (6%).
Median PFS was calculated for 33 patients who com-
pleted the combined chemo-radio treatment, and it wasP
Figure 2 Overall survival of 33 patients with lung cancer, stage III, no
and radiotherapy.20 months (Figure 1). Median OS for the 33 patients
who received both induction chemotherapy and con-
comitant chemo-radiotherapy was 24 months (Figure 2).
Discussion
The treatment of locally advanced NSCLC has been a
controversial issue. It has been well established that con-
current chemo-radiotherapy with Etoposide and Cis-
platin improves survival compared with radiation alone
[1] and it is considered the standard of treatment for lo-
cally advanced NSCLC. Many other strategies have been
tried in order to overcome the achieved survival plateau,
established around a median 17 months [1]. To date, no
randomized comparisons of consolidation chemotherapy
versus observation after concurrent chemo-radiation have
shown a survival benefit in locally advanced NSCLC
[3,25]. The induction chemotherapy strategy has several
theoretical advantages, such as increasing the sensitivity oft operable and treated with induction chemotherapy
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ume to enable a better local control by radiation, allowing
faster eradication of micro-metastatic disease. Several ran-
domized phase II studies were conducted in order to ex-
plore the efficacy of induction chemotherapy followed by
concurrent chemo-radiation versus concomitant treat-
ment followed by consolidation chemotherapy; however
no statistically significant differences were observed [2,26].
The introduction of taxanes, Gemcitabine and Vinorelbine
in combinations with platin compounds as well as the
introduction of new techniques of radiotherapy may im-
prove the therapeutic efficacy of chemo-radiation combin-
ation; nevertheless, the optimal combination, dose intensity,
strategy or timing is still to be defined. In order to study the
feasibility of concurrent chemotherapy with HT, a highly
conformal, new radiation technique, we decided to associate
Docetaxel, known as radio-sensitizing chemotherapeutic
agent. Our goal was to perform a dose-finding study to indi-
viduate the maximum tolerated (MTD) dose of Docetaxel
when associated with HT, assuming that MTD could be dif-
ferent from the one already known of Docetaxel concurrent
with standard radiation therapy. In order to avoid confound-
ing bias, we decided not to associate Docetaxel with Cis-
platin during the concomitant treatment. Being that it is not
ethical to treat patients without Cisplatin, we decided to
offer them an induction treatment with three cycles of Cis-
platin and Docetaxel before concurrent chemo-radiation, al-
though a previous phase III study by Vokes EE et al. had
already stated that induction chemotherapy does not add a
significant survival benefit over concurrent therapy alone
[2]. For this reason, we decided that patients after receiving
three cycles of induction with Cisplatin and Docetaxel were
treated with radiation therapy concurrent with weekly Doce-
taxel, within a dose-finding study for the weekly Docetaxel.
All the patients had multi-level N2 or N3 lymph nodal in-
volvement, confirmed mostly by a non invasive modality,
both CT-scan and PET-CT. In a recent meta-analysis, PET
scanning was superior to CT scanning in the detection of
nodal metastatic disease, with sensitivity of 83% and specifi-
city of 92% [27]. In an attempt to determine the need for in-
vasive staging like mediastinoscopy after PET and CT
imaging, a meta-analysis evaluated the association between
the size of mediastinal lymph nodes and the probability of
malignancy [28]. The authors concluded that the prevalence
of metastasis strongly increases above the 15 mm short-axis
threshold at CT scanning, positioning the need for mediasti-
noscopy only in patients with nodes measuring <15 mm on
CT and negative on FDG-PET or with hilar involvement of
the tumour. We decided to include only patients with
nodes > 15 mm short-axis at CT-scanning and positive on
FDG-PET, and for this reason we do not performed medias-
tinoscopy at staging.
We did not reach a maximum tolerated dose, because
no life-threatening toxicity was observed. We decided tostop the accrual early at a level of weekly docetaxel
38 mg/m2, that being a greater dose than in previous as-
sessments, from both phase-I studies with weekly Doce-
taxel alone and with Docetaxel concomitant with standard
radiotherapy. To our knowledge this is the first study of
Tomotherapy with weekly concurrent chemotherapy in a
dose escalation study of Docetaxel, in the treatment of
NSCLC. There was a previous published study of
Tomotherapy and concurrent chemotherapy, with fixed
dose of chemotherapy, Cisplatin and Docetaxel at a dose
of 20 mg/m2/weekly, each administered weekly and with
radiotherapy fraction size escalation [29]. Although it was
not a primary endopoint for this study, the PFS and OS of
the patients recruited in the study are encouraging, well
above the median data obtained in the previous studies
with chemo-radiation for locally advanced NSCLC; how-
ever they need further validation through phase II, multi-
institutional studies and eventually comparative phase III
trials.
Conclusion
Tomotherapy and concurrent chemotherapy with Doce-
taxel is feasible in advanced NSCLC patients and war-
rants further multi-institutional validation trials.
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